May 17, 2005
Pfizer Inc.'s Drug Sutent Improves Stomach Cancer Survival
Pfizer Inc.'s experimental drug Sutent improved survival and reduced tumor growth in patients with a type of stomach cancer, according to a pivotal-stage trial the company unveiled this weekend. (UPMC Cancer Centers)
Sutent, One of the New 'Targeted' Drugs
The new "smart" drugs are a really exciting element of cancer medicine. One of the new molecularly-targeted cancer drugs is Sutent. It is a "multi-targeted kinase inhibitor." A drug that inhibits several proteins involved in triggering replication in cancer cells. Basically, inhibits various kinases, a type of enzyme that transfe